1 Siegel R,Ma J,Zou Z,et al.Cancer statistics,2014.Ca Cancer J Clin,2017,67:7. 2 Gutierrez-Aguirre CH,GarcãA-Lozano JA,Iglesias-Benavides JL,et al.Comparative analysis of iron status and other hematological parameters in preeclampsia.Hematology,2016,22:36-40. 3 Yang JH,Chou CH,Yang WS,et al.Iron stores and obesity are negatively associated with ovarian volume and anti –Müllerian hormone levels in women with polycystic ovary syndrome.Taiwan J Obstet Gynecol,2015,54:686-692. 4 Crielaard BJ,Lammers T,Rivella S.Targeting iron metabolism in drug discovery and delivery.Nat Rev Drug Discov,2017,16:400. 5 Goforth JB,Anderson SA,Nizzi CP,et a1.Multiple determinants within iron-responsive elements dictate iron regulatory protein binding and regulatory hierarchy.RNA,2010,16:154-169. 6 Jeong SM,Hwang S,Seong RH.Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ROS generation.Biochem Biophys Res Commun,2016,471:373-379. 7 Zhang S,Chen Y,Guo W,et al.Disordered hepcidin-ferroportin signaling promotes breast cancer growth.Cell Signal,2014,26:2539-2550. 8 Czernin J,Phelps ME.Positron emission tomography scanning:current and future applications.Annu Rev Med,2002,53:89-112. 9 Bauckman K,Haller E,Taran N,et al.Iron alters cell survival in a mitochondria -dependent pathway in ovarian cancer cells.Biochem J,2015,466:401-413. 10 Basuli D,Tesfay L,Deng Z,et al.Iron addiction:A novel therapeutic target in ovarian cancer.Oncogene,2017:4089-4099. 11 Yamada Y,Shigetomi H,Onogi A,et al.Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary.Int J Gynecol Cancer,2011,21:1200-1207. 12 Uberti F,Morsanuto V,Lattuada D,et al.Protective effects of vitamin D3 on fimbrial cells exposed to catalytic iron damage.J Ovarian Res,2016,9:34. 13 Ndong C,Toraya Brown S,Kekalo K,et al.Antibody -mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo.Int J Nanomedicine,2015,10:2595-2617. 14 Brard L,Granai CO,Swamy N.Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.Gynecol Oncol,2006,100:116-127. 15 Myers CR.Enhanced targeting of mitochondrial peroxide defense by the combined use of thiosemicarbazones and inhibitors of thioredoxin reductase.Free Radic Biol Med,2016,91:81-92. 16 Dolma S,Lessnick SL,Hahn WC,et al.Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.Cancer Cell,2003,3:285-296. 17 Reed J,Pellecchia M.Ironing Out Cell Death Mechanisms.Cell,2012,149:963-5. 18 Shah MM,Landen CN.Ovarian cancer stem cells:are they real and why are they important? Gynecol Oncol ,2014,132:483. 19 Chen SJ,Kuo CC,Pan HY,et al.Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin -resistant human cervical cancer cells in vitro and in vivo.Oncotarget,2016,7:49310-49321. 20 Peixoto A,Fernandes E,Gaiteiro C,et al.Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.Oncotarget,2016,7:63138-63157. 21 Chen Y,Zhang L,Liu WX,et al.Prognostic significance of preoperative anemia,leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer.Asian Pac J Cancer Prev,2015,16:933-939. 22 Kumagai S,Sugiyama T,Shoji T,et al.Does severe anemia caused by dose -dense paclitaxel -Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.Int J Gynecol Cancer,2011,21:1585-1591. 23 Rocconi RP,Sullivan P,Long B,et al.Treatment of chemotherapyinduced anemia in ovarian cancer patients:does the use of erythropoiesis-stimulating agents worsen survival? Int J Gynecol Cancer,2012,22:786-791.